Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Your 3 Best Profit Opportunities in 2021

By Zhiyuan Sun - Jan 11, 2021 at 6:08AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Add these top growth stocks to your portfolio before it's too late.

The coronavirus pandemic has wreaked havoc over the past year -- but that doesn't make this a bad time to start investing. Since last January, the S&P 500 is up nearly 17.6% to breach new all-time highs.

After the emergence of a new bull market, buying companies with substantial business growth at the right price is a surefire way to put momentum into your portfolio. Today, let's look at why a semiconductor giant, a coronavirus vaccine drugmaker, and a medical cannabis company are among the three best profit opportunities for 2021. 

Man holding cash and laptop.

Image source: Getty Images.

1. Taiwan Semiconductor Manufacturing 

Taiwan Semiconductor Manufacturing, or TSMC ( TSM -0.16% ), is the world's largest contract manufacturer of semiconductors, with more than 56% market share in the chipmaking sector. For its full fiscal 2020, which ends this month, the company expects it can grow its revenue by more than 20% year over year to $84.6 billion. What's more, TSMC is highly profitable, with a stunning 38.5% profit margin.

As of now, the company produces 10,761 different products for smartphones and home personal computers. To meet its goal of commencing 3-nanometer semiconductor production by 2022, it invests about $20 billion per year of its sales in capital expenditures to ramp up production for new technologies.

With annual targets of 20% return on equity and 5% to 10% earnings growth for the next few years, TSMC is a top blue-chip growth stock. Besides, the company also pays a dividend of 1.49% per year, which has never been reduced since its inception in 2004. At 37 times earnings, TSMC's premium undoubtedly reflects for its potential.

2. Pfizer 

Pfizer ( PFE -5.14% ) has been among the hottest coronavirus stocks since the company and its partner BioNTech ( BNTX -18.67% ) received regulatory clearance for their coronavirus vaccine, BNT162b2. The vaccine is 95% effective at preventing COVID-19, with no severe side effects aside from minor occurrences of headache or fatigue.

Governments worldwide have already placed 870 million orders for the vaccine. At a price of $19.50 per dose, this means that Pfizer may already have close to $8.5 billion in potential revenue in the bag, after accounting for a 50-50 gross profit split with BioNTech. The two firms also plan to scale their production capacity to 1.3 billion doses this year.

That's fantastic news, as Pfizer is in dire need of new catalysts to grow its revenue. Last year, the company spun off its generic drug business, Upjohn, because of fierce competition in that sector. Pfizer's agreement meant a loss of $8.5 billion in annual revenues and $0.55 in earnings per share (EPS).

For 2020, the company expects to generate $42.4 billion in revenue from its core biopharma business and $2.38 EPS. Between now and 2025, Pfizer projects it can grow its sales by 6% per year, excluding the effects of the coronavirus vaccine.

Right now, Pfizer's stock is only valued at 24 times earnings and 4 times sales. It also pays a handsome dividend of 4% per year, about twice the S&P 500 average of 2%. If you're looking for a biotech that's primed for growth, look no further than Pfizer. 

3. GW Pharmaceuticals 

GW Pharmaceuticals ( GWPH ) currently markets the first-ever cannabis-based treatment approved for certain types of seizures in the U.S. and the European Union. The drug is called Epidiolex, and it is 50% effective in preventing seizures. In the first month of 2020, GW Pharmaceuticals' flagship drug generated an impressive $378.6 million in revenue.

Aside from Epidiolex, GW Pharmaceuticals has ambitious plans to use a THC/CBD mixture, nabiximols, to treat patients with multiple sclerosis. The company expects it can address a further 1 million patients if nabiximols is successful in phase 3 clinical testing. Between 26% and 50% of patients with multiple sclerosis are already self-medicating with various forms of cannabis.

Right now, the stock is a bit expensive at 7.64 times sales. However, it's reassuring that Epidiolex will have patent protection up until 2035. That gives the company more than a decade to expand its cash flow. For those who are passionate about marijuana stocks, GW Pharmaceuticals is an enticing choice. 

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
$51.48 (-5.14%) $-2.79
Taiwan Semiconductor Manufacturing Company Limited Stock Quote
Taiwan Semiconductor Manufacturing Company Limited
$119.14 (-0.16%) $0.19
GW Pharmaceuticals plc Stock Quote
GW Pharmaceuticals plc
BioNTech SE Stock Quote
BioNTech SE
$279.83 (-18.67%) $-64.23

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/07/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.